Ardelyx to progress pipeline after $30 million series B
This article was originally published in Scrip
Executive Summary
California-based Ardelyx has closed a series B preferred stock financing of $30 million, the proceeds from which will be used to advance its pipeline, including completing two clinical studies of its investigational product, RDX5791.